Robert W. Baird Issues Pessimistic Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST - Free Report) had its price objective lowered by Robert W. Baird from $54.00 to $44.00 in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The firm currently has an outperform rating on the stock.

Several other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a report on Friday, March 28th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Price Performance

Shares of TWST traded down $1.79 during mid-day trading on Tuesday, reaching $30.82. 1,158,651 shares of the stock traded hands, compared to its average volume of 968,895. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 1 year low of $30.72 and a 1 year high of $60.90. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. The firm has a fifty day moving average price of $38.63 and a 200 day moving average price of $43.66.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, equities research analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 918 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dennis Cho sold 689 shares of the company's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the sale, the insider now directly owns 110,849 shares of the company's stock, valued at $4,173,464.85. This represents a 0.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,991 shares of company stock valued at $742,654. 3.01% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in TWST. Versant Capital Management Inc boosted its position in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the period. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the third quarter valued at approximately $34,000. Finally, Banque Transatlantique SA acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $43,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.